John M. Kane, MD

John M. Kane, MD is the Chairman of our Scientific Advisory Board and the Principal Investigator of our Phase 2 study (LB-102-003). Dr. Kane served as Chair of Psychiatry at The Zucker Hillside Hospital for 34 years and Chair of Psychiatry at The Donald and Barbara Zucker School of Medicine for 12 years. He is Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Co-Director of the Institute for Behavioral Science at the Feinstein Institutes for Medical Research. He earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society, and the Schizophrenia International Research Society. He has been a principal investigator on 23 National Institutes of Health (NIH) grants focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 900 peer-reviewed papers and has been consistently ranked by Thomson Reuters in the top 1% of researchers in his field, based on citations of his work.

Dr. Kane has served on the Board of Scientific Counselors for the National Institute of Mental Health (NIMH), chaired the Psychopharmacologic Drugs Advisory Committee of the FDA, and serves on the editorial boards of numerous journals.

Ira D. Glick, MD

Ira D. Glick, MD has been a member of our Scientific Advisory Board since September 2015. Dr. Glick currently is Professor Emeritus, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, and Adjunct Professor, Department of Psychiatry, New York University School of Medicine.

Dr. Glick joined the faculty of the Stanford University School of Medicine in July, 1993. He has been Professor of Psychiatry at the University of California, San Francisco (UCSF) from 1968 to 1978 and at the Cornell University Medical College from 1978 – 1993. During his tenure at Cornell, he was also Senior Science Advisor to the Director of the National Institute of Mental Health (from 1988 – 1990). Dr. Glick’s research has focused on 1) the effectiveness of psychiatric hospitalization, 2) the current and future treatment of schizophrenia and mood disorders including combining medication and psychotherapy (both individual as well as family therapy) and 3) the diagnosis and treatment of athletes (Sports Psychiatry).

A 1961 graduate of New York Medical College, Dr. Glick is a 1) Distinguished Fellow of the American Psychiatric Association and founding member of both the American Family Therapy Academy and the International Society of Sports Psychiatry (ISSP) and a member of the Board of Directors of the American Society of Clinical Psychopharmacology (ASCP). Dr. Glick has been elected to membership of the American College of Neuropsychopharmacology (ACNP) and the American College of Psychiatrists. He has authored or co-authored more than 200 scientific articles and book chapters, eight books as well as psychopharmacology curriculums for teachers of 1) psychiatric residents, 2) for medical students and 3) for primary care physicians.

He has received numerous awards for his research and teaching including those from the American Psychiatric Association, American College of Neuropsychopharmacology and the Association of Academic Psychiatry – plus the 2014 K P Soo Award from the Am Psychiatric Association – as well as an “exemplary psychiatrist” from the National Alliance for Mental Illnesses (NAMI). In 2017 he received the Dean Award from the American College of Psychiatrists for his research in Schizophrenia. He was appointed Emeritus Professor at Stanford in 2010. He is now (2017) Visiting Professor at three medical schools—Weill Cornell Medical College, NYU, and UC San Diego—and has recently rejoined the faculty at UC San Francisco.

Stefan Leucht, MD

Stefan Leucht, MD has been a member of our Scientific Advisory Board since September 2015. Dr. Leucht has been practicing at the Department of Psychiatry and Psychotherapy of the Technische Universität München, Munich, Germany since 1994. In 2002/2003 he spent a year as a research associate at the Zucker Hillside Hospital, Albert Einstein College of Medicine, in New York. He was appointed associate professor in 2011, and is vice- chairman of the department since 2009. He is also an editor to the Cochrane schizophrenia group. Dr. Leucht’s research focus is psychopharmacology and evidence-based medicine in schizophrenia with a focus on meta-analyses, clinical trials and the improvement of methodology of studies in this area. He also has a research interest in pharmacogenetics, compliance enhancement strategies and medical decision making.

Christoph U. Correll, MD

Christoph U. Correll, MD has been a member of the Company’s Scientific Advisory Board since May 2016. Dr. Correll is professor of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in New York, and Medical Director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital in New York. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City.

Dr. Correll’s research and clinical work focus on the identification, characterization and treatment of adults and youths with severe psychiatric disorders, including the prodrome, first episode, multi-episode and refractory illness phase of psychotic and mood disorders. He further focuses on psychopharmacology and comparative effectiveness, as well as the risk–benefit evaluation of psychotropic medications.

Dr. Correll has authored or co-authored over 450 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Professor Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received over 30 national and international research awards and fellowships for his work. Since 2014, the year of inception of this metric, he has been listed each year by Thomson Reuters in as one of “the most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.

Herbert Y. Meltzer, MD

Herbert Y. Meltzer, MD has been a member of the Company’s Scientific Advisory Board since September 2017. Dr. Meltzer is a Professor of Psychiatry and Physiology and Director of the Translational Neuropharmacology Program at Northwestern University in Chicago, IL. He is also Director of the Schizophrenia Program of Centerstone Mental Health System in Nashville, and chair of the Young Investigator Grant Review Committee for NARSAD. He is chairman of the International Psychopharmacology Algorithm Project ( Dr. Meltzer received his BA from Cornell University, an MA in Chemistry from Harvard, and his MD from Yale University.

Dr. Meltzer has been President of the American College of Neuropsychopharmacology (ACNP) and the Collegium International Neuro-psychopharmacologicum (CINP). He served as editor of Psychopharmacology: The Third Generation of Progress and co-editor of the ACNP journal, Neuropsychopharmacology, and is a member of the editorial board of numerous scientific journals. Dr. Meltzer is the recipient of the Efron and Paul Hoch Awards of the ACNP, the Noyes Prize of the Commonwealth of Pennsylvania, the Edward J. Sachar Award from Columbia University, the Lieber Prize for Schizophrenia Research from NARSAD, the Stanley Dean Award for Research in Schizophrenia of the American College of Psychiatry, the Gold Medal Award of the Society of Biological Psychiatry, the Earl Sutherland Prize for Achievement in Research of Vanderbilt University (2004), the Research Prize of the American Psychiatric Association (2005), the Grant Liddle Award for Clinical Research from Vanderbilt University

(2008) and the Lifetime Achievement Award, Winter Conference on Psychosis (2011). His research interests include: basic and clinical psychopharmacology, pharmacogenomics, and prevention of suicide.